TokenPost·
Novartis Sales Rise 4% as U.S. Patent or Exclusivity Expirations Are Estimated for 2031
Kisqali and Kesimpta grew, while remibrutinib reduced relapse rates versus teriflunomide in two Phase III trials.
More news
- TokenPostTrezor Warns CryptoBilis Safe 5 Buyers of Tampering Risk
- TokenPostHelix BioPharma Reports Fiscal 2026 Loss of C$0.04 Per Share
- TokenPostQuad Sets 2026 Adjusted EBITDA Forecast at $185 Million to $195 Million
- TokenPostBinance Says Employee PC Breach Was Only the First Step in Attack
- TokenPostTrezor Flags Suspected Implant in Safe 5 Sold by CryptoBilis
- TokenPostCanadian Sentenced to 25 Months in Case Tied to 185 Bitcoin (BTC) Theft